IPO Recap | Vaccine biotech Vaxxinity surged 27% in its public debut
![IPO Recap | Vaccine biotech Vaxxinity surged 27% in its public debut](https://ussnsimg.moomoo.com/5582676784952816934.png/bigmoo)
On the last trading day, the NASDAQ Composite index rose0.52%, while the S&P 500 index climbed0.06%, and the Dow Jones Industrial Average dropped0.44%.
On Thursday, there was no traditional IPO filed and seven new stocks officially listed for trading.Biotech companyVaxxinity rose27.31% in first day of trading, valued at $2.08 billion.
![IPO Recap | Vaccine biotech Vaxxinity surged 27% in its public debut](https://ussnsimg.moomoo.com/2765561449098026854.png/bigmoo)
Vaxxinity, founded in 2014,is aPhase 2 biotech company developing vaccine therapies for chronic diseases using synthetic peptides.
The company states synthetic peptide vaccine platform (“Vaxxine Platform”) has the potential to enable a new class of therapeutics that will improve the quality and convenience of care, reduce costs and increase access to treatments for a wide range of indications.
Its Vaxxine Platform is designed to harness the immune system to convert the body into its own “drug factory,” stimulating the production of antibodies with a therapeutic or protective effect.
Its current pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s Disease (“AD”), Parkinson’s Disease (“PD”), migraine and hypercholesterolemia.
![IPO Recap | Vaccine biotech Vaxxinity surged 27% in its public debut](https://ussnsimg.moomoo.com/3855833703637661579.png/bigmoo)
Affirm Holdings, founded in 2012, offers "buy now pay later" loans for online purchases.
The company is building the next geneation platform for digital and mobile-first commerce.
The platform comprises three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Our point-of-sale solution allows consumers to pay for purchases in fixed amounts without deferred interest, hidden fees, or penalties.
It went public in January 12th, 2021 and rose 98.45% in its market debut. As if November 11th, it has a market cap of $42.16 billion, with a listed-to-date return of 209.86%.
![IPO Recap | Vaccine biotech Vaxxinity surged 27% in its public debut](https://ussnsimg.moomoo.com/2754027025807278374.png/bigmoo)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment